{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:23:27Z","timestamp":1792445007750,"version":"4.5.0"},"reference-count":15,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The updated risk stratification system for papillary thyroid cancer (PTC) introduced by the 2025 American Thyroid Association (ATA) guidelines has not yet been validated in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Tertiary care center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Data from 670 PTC patients with complete histopathological and final disease outcome were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome measures<\/jats:title>\n                    <jats:p>We evaluated how patients previously classified by the 2015 ATA risk stratification system are redistributed according to the updated version and assessed the impact of reclassification on final disease outcome prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The reclassification according to the 2025 ATA risk stratification showed that the proportion of \u201clow-risk\u201d PTC decreased by 22.2%, while \u201cintermediate-risk\u201d and \u201chigh-risk\u201d PTC increased by 41.7 and 14.9%, respectively. Cross-comparison between the 2 stratification systems revealed that structural disease persistence in the 2025 \u201clow-risk\u201d and \u201chigh-risk\u201d classes was comparable. The 2025 \u201cintermediate-high-risk\u201d class was similar to the former \u201cintermediate-risk\u201d class, whereas the \u201clow-intermediate-risk\u201d class emerged as a new class, with a risk of structural disease persistence higher than that of the 2015 \u201clow-risk\u201d class (P = .003), but lower than that of the 2015 \u201cintermediate-risk\u201d class (P = .012).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a real-life context, the 2025 ATA risk stratification system led to a shift toward higher-risk classes. The newly defined \u201clow-intermediate-risk\u201d class was the only class that significantly diverged from the classes of the 2015 stratification, with a risk of structural recurrence between the prior \u201clow-risk\u201d and \u201cintermediate-risk\u201d classes, highlighting the need for dedicated prospective studies to address proper management of this newly defined group of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag167","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T11:42:52Z","timestamp":1776339772000},"page":"2883-2889","source":"Crossref","is-referenced-by-count":4,"title":["Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-7144","authenticated-orcid":false,"given":"Claudia","family":"Moneta","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan 20142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5913-1337","authenticated-orcid":false,"given":"Matteo","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan 20142 ,","place":["Italy"]},{"name":"Department of Endocrinology, ASST Santi Paolo e Carlo , Milan 20142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0716-481X","authenticated-orcid":false,"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano , Milan 20145 ,","place":["Italy"]},{"name":"Department of Pathophysiology and Transplantation, University of Milan , Milan 20122 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies and Translational Medicine, University of Milan , Milan 20133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3153-976X","authenticated-orcid":false,"given":"Marina","family":"Lugaresi","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan 20142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Maria","family":"Reali","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan 20142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-4644","authenticated-orcid":false,"given":"Giacomo","family":"Gazzano","sequence":"additional","affiliation":[{"name":"Pathology Unit, IRCCS Istituto Auxologico Italiano , Milan 20145 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2068-9581","authenticated-orcid":false,"given":"Luca","family":"Persani","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano , Milan 20145 ,","place":["Italy"]},{"name":"Department of Medical Biotechnologies and Translational Medicine, University of Milan , Milan 20133 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-0982","authenticated-orcid":false,"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan 20142 ,","place":["Italy"]},{"name":"Department of Endocrinology, ASST Santi Paolo e Carlo , Milan 20142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1534-8216","authenticated-orcid":false,"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, ASST Santi Paolo e Carlo , Milan 20142 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"8","key":"2026091519583439800_dgag167-B1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"1","key":"2026091519583439800_dgag167-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"7","key":"2026091519583439800_dgag167-B3","doi-asserted-by":"crossref","first-page":"8783","DOI":"10.1007\/s13277-015-4533-5","article-title":"Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer","volume":"37","author":"Qu","year":"2016","journal-title":"Tumour Biol"},{"issue":"10","key":"2026091519583439800_dgag167-B4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/jamaoto.2021.1976","article-title":"Association of multifocality with prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis","volume":"147","author":"Kim","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2026091519583439800_dgag167-B5","article-title":"The differences between multifocal and unifocal papillary thyroid carcinoma in unilateral lobe: a meta-analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"2026091519583439800_dgag167-B6","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/lio2.824","article-title":"Clinical outcomes of multifocal papillary thyroid cancer: a systematic review and meta-analysis","volume":"7","author":"Cui","year":"2022","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"8","key":"2026091519583439800_dgag167-B7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/jso.24070","article-title":"Prognostic impact of extra-nodal extension in thyroid cancer: a meta-analysis","volume":"112","author":"Veronese","year":"2015","journal-title":"J Surg Oncol"},{"issue":"4","key":"2026091519583439800_dgag167-B8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jso.24713","article-title":"Extranodal extension of lymph node metastasis as a prognostic indicator of recurrence and survival in papillary thyroid carcinoma","volume":"116","author":"Roh","year":"2017","journal-title":"J Surg Oncol"},{"issue":"3","key":"2026091519583439800_dgag167-B9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.surg.2015.08.033","article-title":"Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: predictive factors and operative management","volume":"159","author":"Ch\u00e9reau","year":"2016","journal-title":"Surgery"},{"issue":"2","key":"2026091519583439800_dgag167-B10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ando.2023.11.007","article-title":"Summary and update on the management of differentiated thyroid cancer in 2023","volume":"85","author":"Raymond","year":"2024","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"2026091519583439800_dgag167-B11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13044-022-00145-1","article-title":"Lobo-isthmectomy in the management of differentiated thyroid cancer","volume":"16","author":"Krajewska","year":"2023","journal-title":"Thyroid Res"},{"issue":"1","key":"2026091519583439800_dgag167-B12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/lio2.356","article-title":"Active surveillance for patients with very low-risk thyroid cancer","volume":"5","author":"Lohia","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"12","key":"2026091519583439800_dgag167-B13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bulcan.2021.07.008","article-title":"[De-escalation strategies in differentiated thyroid cancer]","volume":"108","author":"Hartl","year":"2021","journal-title":"Bull Cancer"},{"issue":"11","key":"2026091519583439800_dgag167-B14","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jamaoto.2020.3260","article-title":"Thyroid cancer clinical guidelines and the de-escalation of care","volume":"146","author":"Haymart","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"2026091519583439800_dgag167-B15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejso.2017.03.005","article-title":"Thyroid cancer surgery guidelines in an era of de-escalation","volume":"44","author":"Kovatch","year":"2018","journal-title":"Eur J Surg Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag167\/68103695\/dgag167.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/10\/2883\/68103695\/dgag167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/10\/2883\/68103695\/dgag167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:58:38Z","timestamp":1789516718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/10\/2883\/8657908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,17]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag167","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,17]]}}}